作者：谭明华，胡海涛，区小卫，廖建南，冯伟清，朱劲涛

单位：佛山市禅城区中心医院 普外科，广东 佛山 528031

Authors:  Tan Minghua, Hu Haitao, Ou Xiaowei, Liao Jiannan, Feng Weiqing, Zhu Jingtao

Unit:  Department of General Surgery, Chancheng District Central Hospital of Foshan City, Foshan 528031, China

摘要：

目的 探讨METTL14与结肠癌的临床病理特点和预后的关系。方法 分别通过免疫组织化学和Western blot的方法分析66例接受根治手术的结肠癌患者中METTL14的表达水平,同时结合TCGA和人类蛋白质图谱图像分类(Human Protein Atlas)数据库,分析METTL14的表达与临床病理特点与临床预后的关系。结果 我们观察到结肠癌组织中的METTL14水平明显低于正常邻近组织。在TCGA数据库中也有类似的发现。本研究的数据显示METTL14的表达与进展的T分期、N分期和TNM分期呈负相关。此外,在TCGA数据库中同样显示Ⅰ期的结肠癌患者METTL14的mRNA水平明显高于Ⅱ、Ⅲ和Ⅳ期患者。本组研究中METTL14阳性和METTL14阴性组的5年生存率分别为73.9%和32.6%,生存差异具有显著的统计学意义。多变量Cox回归分析显示,只有T分期和METTL14表达水平是本组结肠癌患者的独立预后因素。在Human protein atlas数据库中观察到类似的结果。METTL14高表达组与低表达组的生存差异具有统计学意义(分别为70%和59%,P=0.006)。结论 METTL14低表达可能提示结肠癌的恶性肿瘤生物学行为,并可作为评估生存预后的预测生物标志物。  

关键词：  结肠癌; METTL14; 临床病理; 生存预后

Abstract：

Objective METTL14 was known to be involved in all stages in the life cycle of RNA. However, whether METTL14 had a close relationship with the clinical parameters and prognosis of colon cancer was not reported yet. Methods METTL14 was studied in TCGA datasets, Human protein atlas datasets and in 66 colon cancer following radical surgery. The level of METTL14 was evaluated by immunohistochemistry (IHC)and Western blot and correlated with clinicopathological variables and clinical outcome. Results We observed that the level of METTL14 in colon cancer was significantly lower than the one in the normal adjacent tissues. A similar result was found in the TCGA datasets. We confirmed a adverse association between the expression of METTL14 and advanced T stage, N stage and TNM stage. Moreover, METTL14 mRNA level in stage Ⅰ was significantly higher than the one in stage Ⅱ, Ⅲ and Ⅳ. The 5 year survival rate of METTL14 positive and METTL14 negative group was 73.9% and 32.6% in this study, and the survival difference had statistical significance. Multivariate Cox regression analysis revealed that only T stage and the expression of METTL14 were the independent prognostic factors. A similar founding was observed in the Human protein atlas datasets. There was significant difference between METTL14 high expression group and low expression group (70% vs 59%, P=0.006). Conclusions Our findings suggested that low expression of METTL14 could be used to determine the aggressiveness of colon cancer and could be predicted the long-term survival outcome.

Key Words:  Colon cancer; METTL14; Clinicopathological features; Survival outcome